SEC Form 4 · accession 0001127602-15-009601
BIOGEN INC. · BIIB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alfred Sandrock
Officer — Grp SVP, Chief Medical Officer
Period of report
Mar 1, 2015
Accepted (ET)
Mar 3, 2015 · 4:44 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875045
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 1, 2015 | F | 2,826 | $409.59 | D | 12,178 | D | |
| Common Stock | Mar 2, 2015 | S | 100 | $406.40 | D | 12,078 | D | |
| Common StockF2,F3 | Mar 2, 2015 | S | 1,100 | $407.948 | D | 10,978 | D | |
| Common StockF2,F4 | Mar 2, 2015 | S | 600 | $408.98 | D | 10,378 | D | |
| Common StockF2,F5 | Mar 2, 2015 | S | 374 | $410.572 | D | 10,004 | D | |
| Common Stock | Mar 2, 2015 | S | 1,000 | $411.39 | D | 9,004 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.
- F2Full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, the issuer, or a security holder of the issuer.
- F3This represents the weighted average price for shares sold at a range between $407.52 (low) and $408.26 (high).
- F4This represents the weighted average price for shares sold at a range between $408.76 (low) and $409.36 (high).
- F5This represents the weighted average price for shares sold at a range between $410.34 (low) and $410.98 (high).